ESLA: Estrella Immunopharma Inc Financial Statements
Balance sheet, income statement, and cash flow statements for Estrella Immunopharma Inc (ESLA).
$38.20M Market Cap.
ESLA Market Cap. (MRY)
ESLA Shares Outstanding (MRY)
ESLA Assets (MRY)
Total Assets
$4.45M
Total Liabilities
$180.70K
Total Investments
$0
ESLA Income (MRY)
Revenue
$0
Net Income
-$7.31M
Operating Expense
$7.31M
ESLA Cash Flow (MRY)
CF Operations
-$16.07M
CF Investing
$4.96M
CF Financing
$12.79M
ESLA Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $4,454,189 (47.08%) | $3,028,399 (-68.86%) | $9,723,802 (182.62%) | $3,440,626 |
Assets Current | $4,454,189 (61.84%) | $2,752,212 (5149.61%) | $52,427 (287.83%) | $13,518 |
Assets Non-Current | $0 (0%) | $276,187 (-97.14%) | $9,671,375 (182.20%) | $3,427,108 |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Shareholders Equity | $4,273,488 (136.39%) | -$11,742,550 (-420.58%) | -$2,255,685 (-11036.12%) | $20,626 |
Property Plant & Equipment Net | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Cash & Equivalents | $4,165,428 (68.02%) | $2,479,146 (5976.04%) | $40,802 (270.32%) | $11,018 |
Accumulated Other Comprehensive Income | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Total Investments | $0 (0%) | $273,066 (-97.18%) | $9,671,375 (203.18%) | $3,190,004 |
Investments Current | $0 (0%) | $273,066 (0%) | $0 (0%) | $0 |
Investments Non-Current | $0 (0%) | $0 (0%) | $9,671,375 (203.18%) | $3,190,004 |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Trade & Non-Trade Receivables | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Trade & Non-Trade Payables | $0 (0%) | $9,333,146 (2735.39%) | $329,166 (0%) | $0 |
Accumulated Retained Earnings (Deficit) | -$19,500,276 (-59.99%) | -$12,188,553 (-440.31%) | -$2,255,827 (-51473.55%) | -$4,374 |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Tax Liabilities | $40,744 (0%) | $0 (0%) | $224,775 (0%) | $0 |
Total Debt | $0 (0%) | $0 (0%) | $498,600 (177.00%) | $180,000 |
Debt Current | $0 (0%) | $0 (0%) | $498,600 (177.00%) | $180,000 |
Debt Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Total Liabilities | $180,701 (-98.15%) | $9,770,949 (268.29%) | $2,653,041 (-22.43%) | $3,420,000 |
Liabilities Current | $180,701 (-98.15%) | $9,758,224 (809.38%) | $1,073,069 (366.55%) | $230,000 |
Liabilities Non-Current | $0 (0%) | $12,725 (-99.19%) | $1,579,972 (-50.47%) | $3,190,000 |
ESLA Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Selling General & Administrative Expense | $3,201,173 (382.69%) | $663,190 (-51.53%) | $1,368,219 (394.90%) | $276,462 |
Research & Development Expense | $4,108,925 (-60.68%) | $10,451,212 (0%) | $0 (0%) | $457,231 |
Operating Expenses | $7,310,098 (-34.23%) | $11,114,402 (608.14%) | $1,569,527 (113.92%) | $733,693 |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Income Tax Expense | $1,625 (0%) | $0 (0%) | $80,648 (0%) | $0 |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Consolidated Income | -$7,311,723 (34.21%) | -$11,114,402 (-1015.79%) | -$996,104 (-35.77%) | -$733,693 |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Net Income | -$7,311,723 (34.21%) | -$11,114,402 (-1015.79%) | -$996,104 (-35.77%) | -$733,693 |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Net Income Common Stock | -$7,311,723 (34.21%) | -$11,114,402 (-1015.79%) | -$996,104 (-35.77%) | -$733,693 |
Weighted Average Shares | $27,103,964 (2034.10%) | $1,270,041 (-77.96%) | $5,762,911 (476.29%) | $1,000,000 |
Weighted Average Shares Diluted | $27,103,964 (2034.10%) | $1,270,041 (-77.96%) | $5,762,911 (476.29%) | $1,000,000 |
Earning Before Interest & Taxes (EBIT) | -$7,310,098 (34.23%) | -$11,114,402 (-1114.08%) | -$915,456 (-24.77%) | -$733,693 |
Gross Profit | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Operating Income | -$7,310,098 (34.23%) | -$11,114,402 (-608.14%) | -$1,569,527 (-113.92%) | -$733,693 |
ESLA Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | $4,960,647 (1916.65%) | -$273,066 (-100.75%) | $36,170,124 | - |
Net Cash Flow from Financing | $12,793,941 (0%) | $0 (0%) | -$35,564,343 | - |
Net Cash Flow from Operations | -$16,068,306 (-1102.61%) | -$1,336,121 (-28.00%) | -$1,043,848 | - |
Net Cash Flow / Change in Cash & Cash Equivalents | $1,686,282 (204.79%) | -$1,609,187 (-267.34%) | -$438,066 | - |
Net Cash Flow - Business Acquisitions and Disposals | -$112,298 (58.88%) | -$273,066 (0%) | $0 | - |
Net Cash Flow - Investment Acquisitions and Disposals | $5,072,945 (0%) | $0 (0%) | $36,170,124 | - |
Capital Expenditure | $0 (0%) | $0 (0%) | $0 | - |
Issuance (Repayment) of Debt Securities | $0 (0%) | $0 (0%) | $548,600 | - |
Issuance (Purchase) of Equity Shares | $4,572,615 (0%) | $0 (0%) | -$36,112,943 | - |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 | - |
Effect of Exchange Rate Changes on Cash | $0 (0%) | $0 (0%) | $0 | - |
Share Based Compensation | $1,194,653 (191.67%) | $409,595 (0%) | $0 | - |
Depreciation Amortization & Accretion | $0 (0%) | $0 (0%) | $0 | - |
ESLA Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | - | - | - | - |
Profit Margin | - | - | - | - |
EBITDA Margin | - | - | - | - |
Return on Average Equity (ROAE) | -91.70% (-151.75%) | 177.20% (185.81%) | 62.00% | - |
Return on Average Assets (ROAA) | -58.60% (18.95%) | -72.30% (-1802.63%) | -3.80% | - |
Return on Sales (ROS) | - | - | - | - |
Return on Invested Capital (ROIC) | 370.60% (421.14%) | -115.40% (-3018.92%) | -3.70% | - |
Dividend Yield | 0% (0%) | 0% (0%) | 0% | - |
Price to Earnings Ratio (P/E) | -3.89 (-213.88%) | -1.24 (97.35%) | -46.77 | - |
Price to Sales Ratio (P/S) | - | - | - | - |
Price to Book Ratio (P/B) | 8.94 (265.52%) | -5.4 (79.76%) | -26.68 | - |
Debt to Equity Ratio (D/E) | 0.04 (105.05%) | -0.83 (29.25%) | -1.18 (-100.71%) | 165.81 |
Earnings Per Share (EPS) | -0.27 (96.91%) | -8.75 (-3877.27%) | -0.22 (99.97%) | -733.69 |
Sales Per Share (SPS) | 0 (0%) | 0 (0%) | 0 (0%) | 0 |
Free Cash Flow Per Share (FCFPS) | -0.59 (43.63%) | -1.05 (-481.22%) | -0.18 | - |
Book Value Per Share (BVPS) | 0.16 (101.71%) | -9.25 (-2264.71%) | -0.39 (-1961.90%) | 0.02 |
Tangible Assets Book Value Per Share (TABVPS) | 0.16 (-93.12%) | 2.38 (41.32%) | 1.69 (-50.97%) | 3.44 |
Enterprise Value Over EBIT (EV/EBIT) | -5 (16.67%) | -6 (90.91%) | -66 | - |
Enterprise Value Over EBITDA (EV/EBITDA) | -4.58 (20.64%) | -5.77 (91.29%) | -66.22 | - |
Asset Turnover | 0 (0%) | 0 (0%) | 0 | - |
Current Ratio | 24.65 (8640.78%) | 0.28 (475.51%) | 0.05 (-16.95%) | 0.06 |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 |
Free Cash Flow (FCF) | -$16,068,306 (-1102.61%) | -$1,336,121 (-28.00%) | -$1,043,848 | - |
Enterprise Value (EV) | $33,467,818 (-47.80%) | $64,116,491 (5.77%) | $60,618,261 | - |
Earnings Before Tax (EBT) | -$7,310,098 (34.23%) | -$11,114,402 (-1114.08%) | -$915,456 (-24.77%) | -$733,693 |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$7,310,098 (34.23%) | -$11,114,402 (-1114.08%) | -$915,456 | - |
Invested Capital | $108,060 (101.17%) | -$9,208,971 (-201.10%) | $9,108,531 (169.51%) | $3,379,608 |
Working Capital | $4,273,488 (161.00%) | -$7,006,012 (-586.43%) | -$1,020,642 (-371.47%) | -$216,482 |
Tangible Asset Value | $4,454,189 (47.08%) | $3,028,399 (-68.86%) | $9,723,802 (182.62%) | $3,440,626 |
Market Capitalization | $38,195,108 (-39.77%) | $63,410,748 (5.34%) | $60,193,413 | - |
Average Equity | $7,971,520 (227.07%) | -$6,273,421 (-290.60%) | -$1,606,115 | - |
Average Assets | $12,471,140 (-18.85%) | $15,368,430 (-41.94%) | $26,471,271 | - |
Invested Capital Average | -$1,972,662 (-120.49%) | $9,627,927 (-61.32%) | $24,892,992 | - |
Shares | 36,376,293 (521.85%) | 5,849,700 (0.00%) | 5,849,700 (10.48%) | 5,295,000 |
